Advice
On 1 April 2015, the marketing authorisation for BindRen was withdrawn at the request of the marketing authorisation holder.  Please see link to the European Medicines Agency statement.

Medicine details

Medicine name:
colestilan (BindRen)
SMC ID:
939/14
Indication:
Treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis.
Pharmaceutical company
Mitsubishi Pharma Europe Ltd
BNF chapter
Nutrition and blood
Submission type
IRP
Status
Withdrawn
Date advice published:
09 February 2015